ACPU
JAZZ icon

Arrowgrass Capital Partners (US)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-37,873
Closed -$5.72M – 212
2018
Q1 		$5.72M Sell
37,873
-81,929
-68% -$12M 0.2% 69
2017
Q4 		$16.1M Sell
119,802
-27,922
-19% -$3.87M 0.16% 162
2017
Q3 		$21.6M Buy
147,724
+36,816
+33% +$5.57M 0.16% 155
2017
Q2 		$17.2M Buy
110,908
+54,286
+96% +$8.3M 0.13% 205
2017
Q1 		$8.22M Buy
+56,622
New +$7.37M 0.08% 274
2016
Q4 		– Sell
-65,648
Closed -$7.97M – 554
2016
Q3 		$7.97M Sell
65,648
-44,455
-40% -$5.99M 0.11% 157
2016
Q2 		$15.6M Buy
110,103
+32,683
+42% +$4.82M 0.17% 91
2016
Q1 		$10.1M Sell
77,420
-33,546
-30% -$4.18M 0.12% 118
2015
Q4 		$15.6M Buy
110,966
+2,944
+3% +$408K 0.19% 75
2015
Q3 		$14.3M Sell
108,022
-13,169
-11% -$2.27M 0.27% 67
2015
Q2 		$21.3M Buy
121,191
+11,309
+10% +$2.03M 0.32% 62
2015
Q1 		$19M Buy
109,882
+48,621
+79% +$8.34M 0.29% 49
2014
Q4 		$10M Buy
+61,261
New +$10.2M 0.18% 83

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s JAZZ Position: Q2 2018 in Review

Arrowgrass Capital Partners (US) sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2018, closing a stake of 37,873 shares — an estimated $5.72M sold.

Arrowgrass Capital Partners (US) first reported a position in JAZZ in Q4 2014 and held it in 13 quarters. The position peaked at $21.6M in Q3 2017. 376 funds tracked by Wall St. Rank hold JAZZ as of Q2 2018.

  • Arrowgrass Capital Partners (US) reported no remaining Jazz Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 37,873 Jazz Pharmaceuticals shares in Q2 2018, an estimated $5.72M.
  • Arrowgrass Capital Partners (US) first reported a position in Jazz Pharmaceuticals in Q4 2014 and held it in 13 quarters.
  • Arrowgrass Capital Partners (US)'s Jazz Pharmaceuticals position peaked at $21.6M in Q3 2017.
  • 376 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2018.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q2 2018, filed 14 Aug 2018.